

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

PROVISION OF GUARANTEE BETWEEN SUBSIDIARIES

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong.

Reference is made to the announcement of the Company dated December 24, 2024 (the “**Announcement**”) regarding business update in connection with the WuXi ATU business. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

I. OVERVIEW OF THE GUARANTEE

In order to ensure that clients and patients with a pressing need for the WuXi ATU cell therapy services can continue to receive time-critical and life-saving treatments without interruption, and at the same time, valued scientists, technicians and other staff of the WuXi ATU U.S. and UK business can continue to work towards achieving the mission that “every drug can be made and every disease can be treated”, on December 24, 2024 (United States time, after trading hours of The Stock Exchange of Hong Kong Limited), WuXi ATU (Ireland) Holding Limited and WuXi ATU (Hong Kong) Limited (collectively the “**Obligors**”), each being a wholly-owned subsidiary of the Company, and Altaris LLC (including the entities controlled by it, “**Altaris**”), entered into a share purchase agreement (the “**SPA**”) pursuant to which the Obligors have agreed to sell, and Altaris has agreed to purchase, all of the shares in WuXi Advanced Therapies Inc. (“**Advanced Therapies**”), the U.S. operating entity of the WuXi ATU business, and Oxford Genetics Limited (“**Oxford Genetics**”, and together with Advanced Therapies and the purchasers under the SPA, the “**Guaranteed Parties**”), the UK operating entity of the WuXi ATU business, held by the respective Obligors, for cash consideration (the “**ATU Business Transaction**”). On March 7, 2025 (United States time), the completion of the ATU Business Transaction took place in accordance with the SPA.

As part of the transaction arrangements of the ATU Business Transaction, WuXi AppTec International Holdings Limited (the “**Guarantor**”), a wholly-owned subsidiary of the Company, has concurrently with the completion of the ATU Business Transaction, entered into a letter of guarantee (the “**Letter of Guarantee**”). Pursuant to the Letter of Guarantee, the Guarantor has agreed to provide guarantee for the potential indemnity obligations of the Obligors under the SPA (if any) (the “**Guarantee**”). The amount of the Guarantee is determined in accordance with the agreement under the Letter of Guarantee, but the maximum aggregate amount shall be up to but not exceeding, on any date of determination, US\$150,000,000.

The Guarantee does not constitute a connected transaction or a notifiable transaction of the Company under Chapter 14A and Chapter 14 of the Hong Kong Listing Rules, respectively. Further, article 6.2.10 of the Shanghai Stock Exchange’s Guidelines for Self-regulatory Supervision of Listed Companies No. 1 -Standardized Operations stipulates that if a listed company’s controlled subsidiary provides a guarantee for a legal person or other organization within the scope of the listed company’s consolidated financial statements, the listed company shall disclose it in a timely manner after the controlled subsidiary has completed the consideration and approval procedures. As the Guarantee is a guarantee between subsidiaries within the scope of the Company’s consolidated financial statements, and the Guarantor has completed the internal board resolution procedures, it does not need to be submitted to the board of directors or shareholders of the Company for consideration and approval.

II. INFORMATION ON THE OBLIGORS

The information on the Obligors is as follows:

WuXi ATU (Ireland) Holding Limited

Principal business:	Investment consultation, investment management
Registered address:	One Spencer Dock, North Wall Quay Dublin 1, Ireland
Date of incorporation:	January 23, 2020
Principal financial data:	As at December 31, 2024, the total assets is US\$357.2176 million, the total liabilities is US\$0.0396 million, and the net assets is US\$357.1780 million. In 2024, the revenue is US\$0 and the net profit is US\$-36.917 million (unaudited single entity basis)
Shareholding structure:	Indirect wholly-owned subsidiary of the Company

WuXi ATU (Hong Kong) Limited

Principal business:	Investment consultation, investment management
Registered address:	Unit 417, 4/F, Lippo Center Tower Two, No.89 Queensway, Admiralty, Hong Kong
Date of incorporation:	October 22, 2019
Principal financial data:	As at December 31, 2024, the total assets is US\$432.5810 million, the total liabilities is US\$20.162 million, and the net assets is US\$412.4189 million. In 2024, the revenue is US\$0 and the net profit is US\$-130.3870 million (unaudited single entity basis)
Shareholding structure:	Indirect wholly-owned subsidiary of the Company

III. PRINCIPAL TERMS OF THE LETTER OF GUARANTEE

Guarantor

WuXi AppTec International Holdings Limited

Obligors

WuXi ATU (Ireland) Holding Limited and WuXi ATU (Hong Kong) Limited

Arrangements of the Guarantee

The Guarantor agrees that if the Obligors fail to pay and discharge all or any portion of the obligation under the SPA when due and payable (as determined by a final and non-appealable judgment of a chosen court), upon the Guaranteed Parties' demand, the Guarantor shall promptly pay, or cause to be paid, to the Guaranteed Parties the obligation to the extent of such judgment, subject to the Seller Liability Limitation. The amount of the Guarantee is determined in accordance with the agreement under the Letter of Guarantee, but the maximum aggregate amount shall be up to but not exceeding, on any date of determination, US\$150,000,000.

The Letter of Guarantee shall terminate on the five year anniversary of the closing date of the ATU Business Transaction (unless the Guaranteed Parties have delivered a claim notice to a chosen court) or such earlier date as agreed upon under the Letter of Guarantee.

IV. THE NECESSITY AND REASONABLENESS OF THE GUARANTEE

The Guarantee is provided by one wholly-owned subsidiary of the Company to another wholly-owned subsidiary of the Company. The ATU Business Transaction involved in the Guarantee is in line with the Company's core code of conduct of customers first and patients first, will not have any material impact on the results and operations of the Company, is in line with the overall interests and development strategy of the Company, and has necessity. As the Guarantee is between wholly-owned subsidiaries of the Company, the risks associated with the Guarantee are controllable, the Guarantee will not create material adverse impact on the Company's overall day-to-day operations and business development, and is not detrimental to the interests of the Company and its shareholders.

V. DECISION-MAKING OPINION AND AUTHORISATION MATTERS

As the Guarantee is a guarantee between subsidiaries within the scope of the Company's consolidated financial statements, and the Guarantor has completed the internal board resolution procedures, it does not need to be submitted to the board of directors or shareholders of the Company for consideration and approval.

VI. NUMBER OF ACCUMULATED EXTERNAL GUARANTEES AND EXPIRED GUARANTEES

As at the date of this announcement, the aggregate amount of external guarantees provided by the Company and its controlled subsidiaries is US\$1.15 billion, which is equivalent to approximately RMB8.249 billion (with reference to the US\$/RMB central parity rate announced by the China Foreign Exchange Trading Center on March 10, 2025), accounting for approximately 14.97% of the audited net assets of the Company in its most recent financial year (i.e. as at December 31, 2023).

Save for the abovementioned guarantees, as at the date of this announcement, the Company and its subsidiaries have not provided any other external guarantee. In addition, the Company has not provided guarantee to the actual controllers or their related parties.

As at the date of this announcement, the Company does not have any expired guarantees.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, March 10, 2025

As at the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*